SCHEMBL1894080

SCHEMBL1894080

O=C1NCCCc2ccccc21

nearest known ligand 0.78

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
PARP10 Q53GL7 11/20 0.78
PARP11 Q9NR21 8/20 0.78
PARP1 P09874 8/20 0.78
PDPK1 O15530 1/20 0.78
CA12 O43570 1/20 0.59
CA9 Q16790 1/20 0.59
CYP2A6 P11509 1/20 0.53
MAOA P21397 1/20 0.53
MAOB P27338 1/20 0.53
CES1 P23141 1/20 0.48
TUBB4A P04350 1/20 0.47
TUBB P07437 1/20 0.47
TUBA3C P0DPH7 1/20 0.47
TUBA1B P68363 1/20 0.47
TUBA4A P68366 1/20 0.47
TUBB4B P68371 1/20 0.47
TUBB3 Q13509 1/20 0.47
TUBB2A Q13885 1/20 0.47
TUBB8 Q3ZCM7 1/20 0.47
TUBA3E Q6PEY2 1/20 0.47

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL29752161 0.94 PARP10 (0.75) PARP10PARP11PARP1PDPK1CA12
SCHEMBL20076060 0.94 PARP10 (0.75) PARP10PARP11PARP1PDPK1CA12
Oxalic Acid SCHEMBL8187201 0.91 PARP11 (0.66) PARP10PARP11PARP1PDPK1CA12
SCHEMBL67710 0.88 PARP10 (1.00) PARP10PARP11PARP1PDPK1CA12
SCHEMBL29369705 0.88 PARP10 (1.00) PARP10PARP11PARP1PDPK1CA12
Hydrochloric Acid SCHEMBL10647408 0.86 PARP10 (0.96) PARP10PARP11PARP1PDPK1CA12
Hydrochloric Acid SCHEMBL29896921 0.86 PARP10 (0.96) PARP10PARP11PARP1PDPK1CA12
Piperazine SCHEMBL28321362 0.82 PARP10 (0.89) PARP10PARP11PARP1PDPK1CA12
SCHEMBL25292799 0.78 PARP11 (0.82) PARP10PARP11PARP1PDPK1TDP2
SCHEMBL11877329 0.77 TSHR (0.52) PARP10PARP11PARP1PDPK1CA12

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 178 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-20260137700-A1 PHARMACEUTICAL COMBINATION OF PRMT5 INHIBITOR AND DNA DAMAGE-INDUCING SUBSTANCE SK BIOPHARMACEUTICALS CO LTD (KR) 2026-05-21 US disclosed
EP-4735422-A1 SUBSTITUTED CYCLIC COMPOUNDS AND METHODS OF TREATING PHENYLKETONURIA AND OTHER AMINO ACIDURIAS Sanofi (FR) 2026-05-06 EP disclosed
US-20250197390-A1 FUSED HETEROCYCLIC COMPOUND, AND PREPARATION METHOD THEREFOR AND MEDICAL USE THEREOF SHANGHAI HENGRUI PHARMACEUTICAL CO., LTD. (CN) 2025-06-19 US disclosed
WO-2025090514-A1 COVALENT SARM1 INHIBITORS NURA BIO, INC. (US) 2025-05-01 WO disclosed
US-20250109139-A1 TRICYCLIC COMPOUND, AND PREPARATION METHOD THEREFOR AND USE THEREOF CENTER FOR EXCELLENCE IN MOLECULAR CELL SCIENCE, CHINESE ACADEMY OF SCIENCES (CN) 2025-04-03 US disclosed
CN-114621207-B Compound serving as thyroid hormone beta receptor agonist and application thereof 广东东阳光药业股份有限公司 2025-02-11 CN disclosed
WO-2025006827-A1 SUBSTITUTED CYCLIC COMPOUNDS AND METHODS OF TREATING PHENYLKETONURIA AND OTHER AMINO ACIDURIAS GENZYME CORPORATION (US) 2025-01-02 WO disclosed
US-20240383913-A1 THIOPHENE RING COMPOUND, PREPARATION METHOD THEREFOR AND APPLICATION THEREOF SHANGHAITECH UNIVERSITY (CN) 2024-11-21 US disclosed
US-20240226320-A1 DRUG CONJUGATES WITH SELF-STABILIZING LINKERS HAVING IMPROVED PHYSIOCHEMICAL PROPERTIES SEAGEN INC (US) 2024-07-11 US disclosed
US-20240051951-A1 BICYCLIC COMPOUND AND USE THEREOF SK BIOPHARMACEUTICALS CO., LTD. (KR) 2024-02-15 US disclosed
US-6107308-A ANTIHISTAMINE; LEUTRIENE ANTAGONIST KOWA CO., LTD. (JP) 2000-08-22 US disclosed
US-5723475-A Arylpiperidine and arylpiperazine derivatives and medicament containing the same SUNTORY LIMITED (JP) 1998-03-03 US disclosed
EP-0757986-A1 ARYLPIPERIDINE AND ARYLPIPERAZINE DERIVATIVES AND DRUGS CONTAINING THE SAME SUNTORY LIMITED (JP) 1997-02-12 EP disclosed
EP-0292840-B1 Cyclic amine derivatives, medicaments containing these compounds and procedure for their preparation THOMAE GMBH DR K (DE) 1995-08-09 EP disclosed
EP-0625978-A1 PIPERAZINE AND PIPERIDINE DERIVATIVES, AND THEIR USE AS ANTIPSYCHOTICS THE WELLCOME FOUNDATION LIMITED (GB) 1994-11-30 EP disclosed
WO-1993016073-A1 PIPERAZINE AND PIPERIDINE DERIVATIVES, AND THEIR USE AS ANTIPSYCHOTICS THE WELLCOME FOUNDATION LIMITED (GB) 1993-08-19 WO disclosed
EP-0259793-B1 NAPHTHYL DERIVATIVES, MEDICAMENTS CONTAINING THEM AND PROCESSES FOR THEIR PREPARATION Dr. Karl Thomae GmbH (DE) 1992-07-01 EP disclosed
US-4313950-A Antireproductive tricyclic ortho-fused nitrogen containing compounds GRUPPO LEPETIT S.P.A. (IT) 1982-02-02 US disclosed
EP-0002624-B1 2-BENZAZEPINE COMPOUNDS, PROCESSES FOR THEIR PREPARATION AND PHARMACEUTICAL COMPOSITIONS CONTAINING THEM SMITHKLINE BECKMAN CORPORATION (US) 1981-10-14 EP disclosed
US-4275066-A 1,2,4-TRIAZOLO(5.1A)ISOINDOZE, TRIAZOLO(5.1A) ISOQUINOLINE OR 1,2,4,-TRIAZOLO (5.1A)(2) BENZAZEPINE CONTRACEPTIVES GRUPPO LEPETIT S.P.A. (IT) 1981-06-23 US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (6 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20240226320-A1 DRUG CONJUGATES WITH SELF-STABILIZING LINKERS HAVING IMPROVED PHYSIOCHEMICAL PROPERTIES CD44, CD47, UACA PARP10 1254/4885PARP11 1717/4885PARP1 1148/4885
US-20260137700-A1 PHARMACEUTICAL COMBINATION OF PRMT5 INHIBITOR AND DNA DAMAGE-INDUCING SUBSTANCE PRMT5, PRMT1, PRMT6 PARP10 29/4885PARP11 18/4885PARP1 16/4885
US-20250197390-A1 FUSED HETEROCYCLIC COMPOUND, AND PREPARATION METHOD THEREFOR AND MEDICAL USE THEREOF RIPK1, RIPK4, MLKL PARP10 601/4885PARP11 386/4885PARP1 733/4885
US-20250109139-A1 TRICYCLIC COMPOUND, AND PREPARATION METHOD THEREFOR AND USE THEREOF PARK7, HADH, BDNF PARP10 2963/4885PARP11 1830/4885PARP1 2316/4885
US-20240051951-A1 BICYCLIC COMPOUND AND USE THEREOF PRMT5, PRMT6, PRMT1 PARP10 58/4885PARP11 78/4885PARP1 202/4885
US-20240383913-A1 THIOPHENE RING COMPOUND, PREPARATION METHOD THEREFOR AND APPLICATION THEREOF TACR1, HTR1F, TPH1 PARP10 3218/4885PARP11 2465/4885PARP1 4178/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.